The short answer
IGF-1 LR3's defining feature is reduced affinity for the binding proteins that normally sequester circulating IGF-1. Those proteins are a regulatory system, not an obstacle, and the compound exists to bypass them. That sits in tension with what the Laron literature reports.
Key facts
- What LR3 removes
- IGF binding protein affinity
- What that system does
- Restrains free IGF-1 availability
- Laron finding
- Congenital deficiency, cancer not observed
- IGF-1R oncology
- Pursued on that rationale
- LR3 clinical development
- None (a cell culture reagent)
- WADA
- Prohibited at all times, class S2
What the binding protein system is for
Six binding proteins hold the overwhelming majority of circulating IGF-1, largely in a ternary complex with IGFBP-3 and the acid-labile subunit. Bound IGF-1 cannot engage its receptor. The system functions simultaneously as a reservoir and a brake, keeping a large circulating pool while holding the active free fraction small and regulated.
Why a growth factor needs a brake
IGF-1 receptors are present on nearly every tissue, and the signal promotes proliferation and opposes cell death. A signal with that reach and that effect requires tight control, and the binding protein system is that control. It is not an inefficiency in the design that an engineer could improve upon.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
What LR3 does to it
Arginine at position 3 and a thirteen-residue N-terminal extension both reduce binding protein affinity. The result is a substantially larger free fraction at the same total concentration. That is the entire purpose of the molecule, and in its intended setting (a culture dish, where secreted binding proteins are an experimental nuisance) it is a sensible design.
The tension in the data
The Laron literature reports that congenital IGF-1 deficiency is associated with absence of cancer, and IGF-1R was pursued as an oncology target on exactly that reasoning. A compound engineered to maximise free IGF-1 availability sits in obvious tension with those findings. Setting them beside each other is the honest thing to do, and this site sells the compound.
What this does and does not establish
It does not establish that IGF-1 LR3 causes cancer. No such finding exists, no clinical programme has examined it, and asserting it would be a claim without evidence. What it establishes is that the compound bypasses a regulatory system whose biology is well documented, and that the documentation points in a direction worth knowing about.
Why the compound stayed in a dish
This is a reasonable part of the explanation for why LR3 was never taken into clinical development. Bypassing IGFBP regulation is desirable in vitro, where it is a nuisance variable, and is a different proposition in an organism where the same system regulates a growth factor acting on every tissue. It remains investigational nowhere, unlicensed everywhere, and prohibited in sport under WADA class S2 at all times.
Frequently asked questions
What does IGF-1 LR3 change?
It reduces affinity for the IGF binding proteins, raising the free fraction available to engage receptors at a given total concentration.
Does that mean it causes cancer?
No such finding exists and no clinical programme has examined it. What can be said is that it bypasses a regulatory system whose biology is well documented.
Why was it never developed clinically?
Bypassing IGFBP regulation is useful in a culture dish where it is a nuisance. In an organism the same system regulates a growth factor acting on every tissue.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedLaron Z, Werner H, Congenital IGF-1 deficiency protects from cancer. Endocr Relat Cancer 2023 (PMID 37343154)pubmed.ncbi.nlm.nih.gov
- PubMedChen HX, IGF-1R as an anti-cancer target: trials and tribulations. Chin J Cancer 2013 (PMID 23601239)pubmed.ncbi.nlm.nih.gov
- PubMedBaxter RC: Horm Res 1994 (PMID 7532612)pubmed.ncbi.nlm.nih.gov
- RefWADA Prohibited Listwada-ama.org
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- Two Hormones, One Feedback LoopGrowth hormone acts on the liver, the liver produces IGF-1, and IGF-1 feeds back to suppress growth hormone. Laron syndrome breaks the loop mid-way.
- Two Receptors Close Enough to Form HybridsThe IGF-1 and insulin receptors share structure and can assemble into hybrids containing subunits of both. Selectivity is therefore never absolute.
- Eighty-Three Residues, and What That ChangesRegulators treat 40 amino acids as the boundary between peptide and protein. At 83 residues, IGF-1 LR3 is well past it - with consequences.
- What Is IGF-1 LR3? Why It Is a Protein, Not a PeptideAn 83-residue engineered IGF-1 analogue built to evade binding proteins. Why it is a protein rather than a peptide, and what that changes.
- IGF Binding Proteins and the Free FractionMost circulating IGF-1 is sequestered in a ternary complex with IGFBP-3 and the acid-labile subunit. That system is what LR3 was designed to evade.